Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation

• Molecular testing may play a role in the determination of targeted therapy treatment options. • Targeted therapy provides treatment options for recurrent cervical cancer. • MEK inhibitor is a treatment option for recurrent cervical cancer in a patient with KRAS mutation.

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Gynecol Oncol Rep
Päätekijät: Lyons, Yasmin A., Frumovitz, Michael, Soliman, Pamela T.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2014
Aiheet:
Short Communication
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4434143/
https://ncbi.nlm.nih.gov/pubmed/26075998
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2014.09.003
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia